1. A child with TSC2/PKD1 contiguous gene deletion syndrome successfully treated with tolvaptan for rapidly enlarging renal cysts.
- Author
-
Muroga C, Yokoyama H, Kinoshita R, Fujimori D, Yamada Y, Okanishi T, Morisada N, Nozu K, and Namba N
- Subjects
- Humans, Female, Child, Gene Deletion, Treatment Outcome, Tolvaptan therapeutic use, Tuberous Sclerosis Complex 2 Protein genetics, TRPP Cation Channels genetics, Antidiuretic Hormone Receptor Antagonists therapeutic use, Tuberous Sclerosis drug therapy, Tuberous Sclerosis genetics, Tuberous Sclerosis complications, Magnetic Resonance Imaging, Polycystic Kidney, Autosomal Dominant drug therapy, Polycystic Kidney, Autosomal Dominant genetics, Polycystic Kidney, Autosomal Dominant complications
- Abstract
Tolvaptan, a vasopressin receptor antagonist, has been shown to be effective in the treatment of renal cysts in ADPKD. However, tolvaptan is not indicated for pediatric patients, and reports of its use are rare, making its efficacy and adverse reactions unclear. Herein, we present the case of an 11-year-old girl who had vitiligo from birth. She was diagnosed with West syndrome at 6 months of age and tuberous sclerosis at 2 years of age. At the age of 6 years, an abdominal magnetic resonance imaging (MRI) revealed multiple bilateral renal cysts, and she was diagnosed with ADPKD. Abdominal MRI scans performed at 10 years and 11 years showed rapid renal cyst enlargement, and the renal prognosis was judged to be poor. The patient was treated with tolvaptan to delay cyst exacerbation. There were no apparent adverse events after the initiation of treatment, and the MRI performed 12 months after treatment initiation showed that renal cyst enlargement was suppressed. The results suggest that tolvaptan may be effective in pediatric patients with severe ADPKD who have rapidly enlarging renal cysts, although evaluation of renal cyst enlargement and side effects should be continued., (© 2024. The Author(s), under exclusive licence to Japanese Society of Nephrology.)
- Published
- 2024
- Full Text
- View/download PDF